Jie Yang

A narrative review of adaptive Phase I/II clinical trial designs for drug combinations in oncology

Background Adaptive Phase I/II designs can jointly use toxicity and efficacy information to guide dose allocation and regimen selection. These designs are particularly relevant for oncology drug-combination trials, where the optimal regimen may not coincide with the maximum tolerated dose. Methods We conducted a struct...